Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine

References

• Hasle H, Kerndrup G, Jacobsen BB. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia. 1995;9(9):1569–1572.
   PubMed Web of Science ®Google Scholar
• Sakashita K, Matsuda K, Koike K. Diagnosis and treatment of juvenile myelomonocytic leukemia. Pediatrics International. Pediatr Int. 2016;58(8):681–690. doi:10.1111/ped.13068.
   PubMedGoogle Scholar
• Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29(4):465–468. doi:10.1038/ng772.
   PubMed Web of Science ®Google Scholar
• Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34(2):148–150. doi:10.1038/ng1156.
   PubMed Web of Science ®Google Scholar
• Kalra R, Dale D, Freedman M, et al. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood. 1995;86(12):4579–4586.
   PubMed Web of Science ®Google Scholar
• Flotho C, Valcamonica S, Mach-Pascual S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13(1):32–37. doi:10.1038/sj.leu.2401240.
   PubMed Web of Science ®Google Scholar
• Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997; 89:3534–3543.
   Google Scholar
• Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd international JMML symposium. Leuk Res. 2009;33(3):355–362. doi:10.1016/j.leukres.2008.08.022.
   PubMed Web of Science ®Google Scholar
• Aric OM, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood. 1997;90(2):479–488. doi:10.1182/blood.V90.2.479.
   PubMed Web of Science ®Google Scholar
• Honda Y, Tsuchida M, Zaike Y, et al. Clinical characteristics of 15 children with juvenile myelomonocytic leukaemia who developed blast crisis: MDS Committee of Japanese Society of Paediatric Haematology/Oncology. Br J Haematol. 2014;165(5):682–687. doi:10.1111/bjh.12796.
   PubMed Web of Science ®Google Scholar
• Luna-Fineman S, Shannon KM, Atwater SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. 1999;93(2):459–466.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood. 2015;125(7):1083–1090. doi:10.1182/blood-2014-08-550483.
   PubMed Web of Science ®Google Scholar
• Lilleyman JS, Harrison JF, Black JA. Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine. Blood. 1977;49(4):559–562. doi:10.1182/blood.V49.4.559.559.
   PubMed Web of Science ®Google Scholar
• Bergstraesser E, Hasle H, Rogge T, et al. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria. Pediatr Blood Cancer. 2007;49(5):629–633. doi:10.1002/pbc.21038.
   PubMed Web of Science ®Google Scholar
• Mutz ID, Zoubek A. Transient response to alpha-interferon in juvenile chronic myelomonocytic leukemia. Pediatr Hematol Oncol. 1988;5(1):71–75. doi:10.3109/08880018809031255.
   PubMed Web of Science ®Google Scholar
• Castleberry RP, Emanuel PD, Zuckerman KS, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med. 1994;331(25):1680–1684. doi:10.1056/NEJM199412223312503.
   PubMed Web of Science ®Google Scholar
• Niemeyer CM, Loh ML, Cseh A, et al. Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica. 2015;100(1):17–22. doi:10.3324/haematol.2014.109892.
   PubMed Web of Science ®Google Scholar
• Lutz P, Zix-Kieffer I, Souillet G, et al. Juvenile myelomonocytic leukemia: Analyses of treatment results in the EORTC Children’s Leukemia Cooperative Group (CLCG). Bone Marrow Transplant. 1996;18:1111– 1116.
   PubMed Web of Science ®Google Scholar
• Laver J, Kushner BH, Steinherz PG. Juvenile chronic myeloid leukemia: therapeutic insights. Leukemia. 1987;1(10):730–733.
   PubMed Web of Science ®Google Scholar
• Arico M, Nespoli L, Caselli D, et al. Juvenile chronic myeloid leukaemia and alpha-interferon. Eur J Pediatr. 1989;148(4):379–380. doi:10.1007/BF00444141.
   PubMed Web of Science ®Google Scholar
• Mirro J, Dow LW, Kalwinsky DK, et al. Phase I-II study of continuous-infusion high-dose human lymphoblastoid interferon and the in vitro sensitivity of leukemic progenitors in non-lymphocytic leukemia. Cancer Treat Rep. 1986;70(3):363–367.
   PubMedGoogle Scholar
• Hazani A, Barak Y, Berant M, et al. Congenital juvenile chronic myelogenous leukemia: therapeutic trial with interferon alpha-2. Med Pediatr Oncol. 1993;21(1):73–76. doi:10.1002/mpo.2950210115.
   PubMedGoogle Scholar
• Suttorp M, Rister M, Schmitz N. Interferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia. Med Pediatr Oncol. 1994;22(5):358–359. doi:10.1002/mpo.2950220513.
   PubMedGoogle Scholar
• Castleberry RP, Chang M, Maybee D, et al. A phase II study of 13- cis retinoic acid (CRA) in juvenile myelomonocytic leukemia (JMML). A Pediatric Oncology Group (POG) study. Blood. 1997; 90:364a. abstract).
   Web of Science ®Google Scholar
• Locatelli F, Nollke P, Zecca M, European Blood and Marrow Transplantation Group, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105(1):410–419. doi:10.1182/blood-2004-05-1944.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Crotta A, Ruggeri A, et al. Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study. Blood. 2013;122(12):2135–2141. doi:10.1182/blood-2013-03-491589.
   PubMed Web of Science ®Google Scholar
• Stieglitz E, Mazor T, Olshen AB, et al. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun. 2017;8(1):2127–2128. doi:10.1038/s41467-017-02178-9.
   PubMedGoogle Scholar